Ameliorative effect of resveratrol against cymoxanil‐mancozeb induced toxicity in rats
This study was conducted to evaluate the cymoxanil‐mancozeb (CM) toxicity and investigate the ameliorative effect of resveratrol (Res) against cymoxanil‐mancozeb toxicity. Forty rats were divided into four groups; the first group was used as a control group, the second group was exposed to Res only...
Saved in:
Published in | Journal of biochemical and molecular toxicology Vol. 37; no. 6; pp. e23347 - n/a |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.06.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | This study was conducted to evaluate the cymoxanil‐mancozeb (CM) toxicity and investigate the ameliorative effect of resveratrol (Res) against cymoxanil‐mancozeb toxicity. Forty rats were divided into four groups; the first group was used as a control group, the second group was exposed to Res only at a dose of 20 mg/kg body weight for 4 weeks, and the third group was administered CM only at a dose of 799 mg/kg body weight for 4 weeks, The fourth group was co‐treated with Res+CM for 4 weeks. Blood samples were analyzed for hematological and biochemical parameters. The comet assay was done on liver and blood specimens and histopathological examinations of the liver and intestine. The results demonstrated that CM exposure caused a significant increase in WBCs, lymphocytes, granulocytes, monocytes ALT, AST, ALP, and GGT, and total cholesterol and triglycerides levels accompanied by a decrease in HGB, HCT, RBCs and MCV, MCH, MCHC, HDL and glucose levels with no significant DNA damage in liver and blood. CM mixture induced severe pathological changes in small intestine and liver. Co‐treatment of Res with CM improved hematological picture, lipid and glucose profiles also liver enzymes and decreased changes in the architecture of the liver and intestine. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1095-6670 1099-0461 |
DOI: | 10.1002/jbt.23347 |